Bae Ah Young, Kim Do Hyun, Hwang Se Hwan
Department of Otolaryngology-Head and Neck Surgery, Bucheon Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Department of Otolaryngology-Head and Neck Surgery, Seoul Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
J Rhinol. 2024 Mar;31(1):1-7. doi: 10.18787/jr.2024.00006. Epub 2024 Mar 31.
This study aimed to evaluate the impact of topical platelet-rich plasma (PRP) injection on persistent refractory olfactory dysfunction after COVID-19 infection.
A systematic review was conducted, focusing on studies that compared the efficacy of topical PRP treatment with a control group (receiving either placebo or no treatment) in ameliorating olfactory dysfunction. Pre- and post-treatment comparisons were evaluated, along with a subgroup analysis of olfactory function evaluation.
The analysis revealed a significant improvement in olfactory scores between 1 to 3 months post-treatment (standardized mean difference=1.4376; 95% confidence interval [CI]=0.5934-2.2818; I=84.1%) in the treatment group compared to the control group. Moreover, a notable disparity was observed between the two groups in the incidence of substantial recovery from anosmia or hyposmia (odds ratio=8.6639; 95% CI=2.9752-25.2292; I=0.0%). PRP treatment led to a clinically significant increase in the threshold, discrimination, and identification (TDI) score for the Sniffin' Sticks test by >5.5 (minimum clinically significant difference; mean difference, 6.3494; 95% CI=4.0605-8.6384; I=0.0%), as confirmed by verified examinations. The odds ratio for significant improvement among patients after treatment was determined to be 0.7654 (95% CI=0.6612-0.8451). Furthermore, all TDI subdomains exhibited significant and comparable improvements post-treatment.
This meta-analysis indicates that the injection of PRP into the olfactory fissure or surrounding mucosal areas is an effective treatment for persistent refractory olfactory dysfunction.
本研究旨在评估局部注射富血小板血浆(PRP)对新型冠状病毒肺炎(COVID-19)感染后持续性难治性嗅觉功能障碍的影响。
进行了一项系统评价,重点关注比较局部PRP治疗与对照组(接受安慰剂或不治疗)改善嗅觉功能障碍疗效的研究。评估了治疗前后的比较情况,以及嗅觉功能评估的亚组分析。
分析显示,与对照组相比,治疗组在治疗后1至3个月时嗅觉评分有显著改善(标准化平均差=1.4376;95%置信区间[CI]=0.5934 - 2.2818;I²=84.1%)。此外,两组在嗅觉减退或嗅觉丧失显著恢复的发生率上存在显著差异(优势比=8.6639;95% CI=2.9752 - 25.2292;I²=0.0%)。经验证检查证实,PRP治疗使嗅觉棒测试的阈值、辨别力和识别力(TDI)评分在临床上显著提高>5.5(最小临床显著差异;平均差,6.3494;95% CI=4.0605 - 8.6384;I²=0.0%)。治疗后患者显著改善的优势比确定为0.7654(95% CI=0.6612 - 0.8451)。此外,所有TDI亚领域在治疗后均表现出显著且相当的改善。
这项荟萃分析表明,将PRP注射到嗅裂或周围黏膜区域是治疗持续性难治性嗅觉功能障碍的有效方法。